Showing results (151-160 of 174) with videos related to
Sort By:
Pageof 18
Acta Crystallographica. Section D, Structural Biology|June 27, 2025
Crystal structure of coagulation factor XII N-terminal domains 1-5Muhammad Saleem, Chan Li, Bubacarr G Kaira, et al.Journal of Thrombosis and Haemostasis : JTH|February 16, 2023
Recommendation on the nomenclature for anticoagulants: updated communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Commitee on the Control of AnticoagulationGeoffrey D Barnes, Walter Ageno, Lana A Castellucci, et al.Blood|July 17, 2010
A role for factor XIIa-mediated factor XI activation in thrombus formation in vivoQiufang Cheng, Erik I Tucker, Meghann S Pine, et al.Blood|June 4, 2021
The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trialChristina U Lorentz, Erik I Tucker, Norah G Verbout, et al.Blood|January 11, 2014
Factor XII inhibition reduces thrombus formation in a primate thrombosis modelAnton Matafonov, Philberta Y Leung, Adam E Gailani, et al.Immunity|September 25, 2020
Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly ProtectiveAnders Madsen, Ya-Nan Dai, Meagan McMahon, et al.The Journal of Biological Chemistry|December 20, 2024
The physicochemical properties of lipopolysaccharide chemotypes regulate activation of the contact pathway of blood coagulationAndré L Lira, Berk Taskin, Cristina Puy, et al.Blood Advances|February 28, 2019
Inhibition of contact-mediated activation of factor XI protects baboons against S aureus-induced organ damage and deathRobert Silasi, Ravi Shankar Keshari, Cristina Lupu, et al.Blood Advances|January 15, 2020
Differential roles of factors IX and XI in murine placenta and hemostasis under conditions of low tissue factorSteven P Grover, Clare M Schmedes, Alyson C Auriemma, et al.Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|August 29, 2022
Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke PreventionMukul Sharma, Carlos A Molina, Kazunori Toyoda, et al.Pageof 18